Teva Pharmaceutical Industries Limited

NYSE:TEVA Voorraadrapport

Marktkapitalisatie: US$40.0b

Teva Pharmaceutical Industries Toekomstige groei

Future criteriumcontroles 2/6

Teva Pharmaceutical Industries zal naar verwachting groeien in winst en omzet met respectievelijk 9.1% en 2.3% per jaar. De winst per aandeel zal naar verwachting groeien met 10.8% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 22.1% zijn.

Belangrijke informatie

9.1%

Groei van de winst

10.80%

Groei van de winst per aandeel

Pharmaceuticals winstgroei14.4%
Inkomstengroei2.3%
Toekomstig rendement op eigen vermogen22.10%
Dekking van analisten

Good

Laatst bijgewerkt18 May 2026

Recente toekomstige groei-updates

Recent updates

Seeking Alpha • May 11

Teva's CNS Portfolio Is Growing, But Valuation Is Stretched

Summary Sales of Teva's CNS portfolio, including Ajovy, Uzedy, and Austedo, rose 42.1% year-on-year to $837 million in Q1. In my opinion, this growth, combined with the acquisition of Emalex, was the driver that pushed TEVA stock from the lower end of the distribution to $35.70. As I'll explain below, Emalex's ecopipam is significantly less effective than Abilify, for which generic versions have been produced since 2015, including by Teva. Results from Phase 3s evaluating duvakitug, developed jointly with Sanofi, for the treatment of Crohn's disease and UC will not be available until the end of 2028/Q1 2029. Given that TEVA trades at the non-GAAP P/E ratio of 14.93x, which is 65.9% higher than Sanofi's, I continue to cover the Israeli generic drug giant with a 'Sell' rating. Read the full article on Seeking Alpha
Narratiefupdate • May 04

TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal

Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.
Nieuw narratief • Apr 26

Teva Pharmaceutical Industries (TEVA): The Generic Giant Pivots Toward an Innovative Supercycle

Teva Pharmaceutical Industries Ltd. (TEVA) , the global vanguard of generic medicine and a rising force in innovative biopharmaceuticals, enters the weekend of Sunday, April 26, 2026 , in a state of high-conviction growth.
Narratiefupdate • Apr 16

TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal

Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.
Nieuw narratief • Apr 09

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?
Narratiefupdate • Apr 02

TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal

Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.
Narratiefupdate • Mar 18

TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook

Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.
Narratiefupdate • Mar 04

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.
Narratiefupdate • Feb 18

TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook

Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.
Narratiefupdate • Feb 04

TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook

Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.
Narratiefupdate • Jan 20

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating

Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.
Narratiefupdate • Jan 06

TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.
Narratiefupdate • Dec 22

TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.
Narratiefupdate • Dec 08

TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins

Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.
Narratiefupdate • Nov 24

TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches

Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.
Analyseartikel • Nov 13

We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative

Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...
Analyseartikel • Nov 12

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...
Narratiefupdate • Nov 07

TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears

Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.
Narratiefupdate • Oct 23

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.
Narratiefupdate • Oct 09

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.
Narratiefupdate • Sep 25

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
Analyseartikel • Jul 14

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
User avatar
Nieuw narratief • Apr 23

Generics And Biosimilars Pipeline And Expansion Will Define Progress

The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.
Seeking Alpha • Feb 28

Teva Pharmaceutical: A Risky Bet With Potential Upside

Summary Teva Pharmaceutical faces challenges with high debt, legal issues, and pricing pressure, but is shifting focus to higher-margin biosimilars and specialty drugs. Despite trading at a low 6.56x forward earnings, Teva's high debt-to-EBITDA ratio and declining earnings are significant concerns. The company's push into biosimilars is promising, but execution and market competition will be critical for success. Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and profitability issues. Read the full article on Seeking Alpha
Seeking Alpha • Jan 30

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Summary Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027. Teva's aggressive debt reduction enhances financial stability, paving the way for future shareholder-friendly activities like dividends or share repurchases. A 12-month price target of $25/share, 10x FY 2025 non-GAAP EPS estimates seems achievable should Teva outperform lowered EPS and sales estimates. Read the full article on Seeking Alpha
Seeking Alpha • Dec 27

Duvakitug And Teva's Growth: A Game Changer In Pharma

Summary On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year. Meanwhile, sales of Teva's generics in North America reached $1.09 billion for the three months ended September 30, 2024, up 30.4% from the same period a year earlier. In addition to decreasing its net debt by more than $1 billion in the first three quarters of2024, in this article, you will discover why I continue to cover Teva Pharmaceuticals with a “Buy” rating. Read the full article on Seeking Alpha
Seeking Alpha • Dec 04

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Summary Teva's stock has risen 105% in two years, outperforming the S&P 500, but it is no longer a bargain at $17.50 per share. The company's focus on debt reduction has been successful, with net debt falling to $15.70 billion, but high interest expenses remain a concern. Key drugs like AUSTEDO®, AJOVY®, and UZEDY® are driving revenue growth, with AUSTEDO® showing the most promise due to long patent life and rising demand. Despite strong performance and growth in generics and biosimilars, I recommend holding Teva stock, valuing it at $15 per share. Read the full article on Seeking Alpha
Seeking Alpha • Oct 23

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Summary Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend. A key risk in pharma space, both financial and reputational, is facing costly legal/regulatory cases. Read the full article on Seeking Alpha
Seeking Alpha • Sep 09

Cheap Teva Stock Should Reward Patient Investors

Summary Teva is poised to benefit from rising demand for generic drugs due to a favorable macro and political environment. The company's valuation is attractive despite its high debt load, which it is likely to manage effectively. Teva's generic drug revenue surged 16% in Q2, and the unit's continued growth is expected to significantly boost the firm's overall revenue. Governments and consumers are increasingly opting for cost-effective generic drugs. The latter trend is likely to help boost demand for Teva's generic products. Read the full article on Seeking Alpha
Seeking Alpha • Aug 14

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Summary Step by step, Teva's management is making progress in transforming it from a generic drugmaker into one that will play a key role in the fight against immune-related disorders. Its revenue was about $4.16 billion in the second quarter of 2024, up 7.2% year-on-year. So, in addition to the growth in sales of its generic products, there is also increased demand for innovative medications, including Austedo and Uzedy. One of the key milestones in Teva's history will be the publication of results from a clinical trial evaluating the efficacy of duvakitug in the treatment of inflammatory bowel disease in late 2024. Ultimately, I continue to cover Teva Pharmaceutical with a 'Buy' rating. Read the full article on Seeking Alpha
Seeking Alpha • Jul 26

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Summary Teva Pharmaceutical's stock is up 69% since December, driven by legal resolution, blockbuster drugs, debt reduction, and new product launches. Recent developments include the launch of biosimilars and generics, positive data on Uzedy and Ajovy, and an accelerated timeline for TEV-48574. Financially, Teva's current ratio is under 1, with upcoming debt maturities posing a challenge. Recommendation remains "Hold" pending Q2 earnings. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:TEVA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202817,9472,3933,7883,0108
12/31/202717,2692,5193,0232,57511
12/31/202616,5641,8252,2151,57910
3/31/202617,3491,5651,1721,714N/A
12/31/202517,2581,4101,1481,649N/A
9/30/202516,7767135781,066N/A
6/30/202516,628-1578901,390N/A
3/31/202516,616-1,2867651,266N/A
12/31/202416,544-1,6397491,247N/A
9/30/202416,772-9591,3681,856N/A
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3366081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825413941N/A
12/31/201916,887-999N/A748N/A
9/30/201916,396-4,048N/A577N/A
6/30/201916,831-4,007N/A673N/A
3/31/201917,355-3,559N/A1,062N/A
12/31/201818,271-2,399N/A2,446N/A
9/30/201819,693-11,059N/A2,938N/A
6/30/201820,781-10,256N/A3,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A
6/30/201520,1742,548N/A6,010N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei TEVA ( 9.1% per jaar) ligt boven de spaarquote ( 3.5% ).

Winst versus markt: De winst van TEVA ( 9.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.7% per jaar).

Hoge groeiwinsten: De winst van TEVA zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van TEVA ( 2.3% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van TEVA ( 2.3% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen TEVA zal naar verwachting over 3 jaar hoog zijn ( 22.1 %)

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/21 19:29
Aandelenkoers aan het einde van de dag2026/05/21 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Teva Pharmaceutical Industries Limited wordt gevolgd door 46 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Glen SantangeloBarclays